A Phase II Study of Anti-PD-1 (Pembrolizumab) in Combination With Hormonal Therapy in Patients With Hormone Receptor (HR)-Positive Localized Inflammatory Breast Cancer (IBC) Who Did Not Achieve a Pathological Complete Response (pCR) to Neoadjuvant Chemotherapy

Trial Profile

A Phase II Study of Anti-PD-1 (Pembrolizumab) in Combination With Hormonal Therapy in Patients With Hormone Receptor (HR)-Positive Localized Inflammatory Breast Cancer (IBC) Who Did Not Achieve a Pathological Complete Response (pCR) to Neoadjuvant Chemotherapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Inflammatory breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jan 2017 Planned primary completion date changed from 1 Dec 2020 to 1 Jan 2020.
    • 26 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 25 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top